title: Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus.
abstract: OBJECTIVE
  Status epilepticus (SE) is a medical emergency associated with a high mortality. Clinical series have suggested that mortality after SE has decreased. No studies have systematically examined trends in incidence, mortality, and case fatality after SE in a well-defined population.
  
  
  METHODS
  All first episodes of SE receiving medical attention between January 1, 1935, and December 31, 1984, were ascertained through the Rochester Epidemiology Project Records-Linkage System and followed up until death or study termination (February 1, 1996). We calculated incidence rates in the 50-year period (1935-1984), while we considered mortality and case-fatality in the last 30-year period (1955-1984).
  
  
  RESULTS
  Incidence of SE increased over time to 18.1/100,000 (1975 through 1984). The increase was related to an increased incidence in the elderly and to the advent of myoclonic SE after cardiac arrest, a condition not seen in the early decades. In the last decade, approximately 16% of the incidence was due to myoclonic SE. The mortality rates increased from 3.6 per year in the decade 1955-1965 to 4.0/100,000 per year between 1975 and 1984. The 30-day case-fatality (CF) was unchanged, although a trend toward improvement was shown after excluding myoclonic SE.
  
  
  CONCLUSIONS
  Incidence and mortality rates of SE have increased in the last 30 years. Case fatality remained the same. The increased incidence and mortality are due to the occurrence in the last decade of myoclonic SE after cardiac arrest. The mortality in the elderly was twice that of the youngest age group, across all study periods. Changes in the age and cause distribution of SE over time are responsible for the stable survivorship. There is improvement in survivorship in the last decade when myoclonic SE is excluded.
authors.affiliation: Gertrude H. Sergievsky Center, New York, New York 10032, USA.
authors.forename: G
authors.initials: G
authors.lastname: Logroscino
authors.forename: D C
authors.initials: DC
authors.lastname: Hesdorffer
authors.forename: G
authors.initials: G
authors.lastname: Cascino
authors.forename: J F
authors.initials: JF
authors.lastname: Annegers
authors.forename: W A
authors.initials: WA
authors.lastname: Hauser
mesh_terms: D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000927:Anticonvulsants / Q000627:therapeutic use; D004831:Epilepsies, Myoclonic / Q000175:diagnosis / Q000453:epidemiology / Q000401:mortality; D005260:Female; D006323:Heart Arrest / Q000150:complications / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009026:Mortality / Q000639:trends; D011379:Prognosis; D016016:Proportional Hazards Models; D012306:Risk; D017678:Sex Distribution; D013226:Status Epilepticus / Q000175:diagnosis / Q000453:epidemiology* / Q000401:mortality*
chemical_list: D000927:Anticonvulsants